Delivery Order SPE2DB22D3401-SPE2DB25FT5LM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,094.60 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 ml syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. The contract utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Dupixent 300 mg/2 ml syringes with a contract value of $42,767.05. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 26, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $26,522.23 for Dupixent (dupilumab) 300 mg/2 mL syringes on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and is being performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $13,593.94 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This firm fixed-price, non-set-aside contract is classified as a delivery order with an ultimate completion date of September 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe...
- The Defense Logistics Agency awarded a $5,128.38 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Dupixent 200 mg/1.14 ml syringes. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of April 25, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,709.46 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes. The contract, which is a non-set-aside competitive award with firm fixed pricing, is scheduled for completion by August 12, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $29,860.78 for Dupixent 300 mg/2 ml syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract, which is not set-aside, will be performed at the company's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and other inflammatory conditions, making...
- The Defense Logistics Agency awarded a $69,305.82 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml syringes on May 27, 2025, with completion scheduled for May 28, 2025. This firm fixed price contract represents a non-competitive set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly prescribed for severe asthma, eczema, and other inflammatory conditions, making this delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $10,777.92 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL syringes on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $11,966.22 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL syringes on September 5, 2025, with an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT5LMDelivery Order
The Defense Logistics Agency awarded a $31,152.11 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with a completion date of August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. Dupixent is a biologic medication used to treat conditions such as atopic dermatitis, moderate-to-severe asthma, and chronic rhinosinusitis with nasal polyps. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen supplies a broad range of pharmaceutical products and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to meet defense procurement requirements through open competition, with delivery orders ranging substantially in value and covering diverse therapeutic domains essential to military and veteran healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.2k | 8/4/25 |